Horizon Discovery
The Myeloid DNA Reference Standard is the first-to-market, large cell-line derived, myeloid cancer reference standard designed to enable faster, more reliable, and more cost-effective assay validation, to support the market in bringing routine testing into practice. This standard has been developed using Horizon’s specialist gene-editing technology, to deliver a cell line-derived reference standard containing 22 mutations across 19 genes that are commonly associated with myeloid cancer. This provides genetic testing laboratories and assay developers with a tool to effectively validate and optimize myeloid genetic tests with DNA of known genotype which closely mimics the genomic DNA format and mutations present in real patient samples. The Myeloid DNA Reference Standard contains variants in more genes than most clinical material, enabling quality assurance goals to be reached faster.
